On November 6, 2021 Philogen reported its attendance at the Festival of Biologics Basel on November 10, 2021 (Press release, Philogen, NOV 6, 2021, View Source [SID1234594678])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lisa Nadal, 3-year PhD student at Philogen, is giving a lecture entitled "A novel IL12-based immunocytokine targeting Fibroblast Activation Protein (FAP) for the treatment of cancer"

Roberto De Luca, Head of Antibody Therapeutics at Philogen, is giving a lecture entitled "Tripokin: tumor targeted delivery of IL2 potentiated by TNF"

Samuele Cazzamalli, Head of Small Molecule Therapeutics at Philogen, is giving a lecture entitled "Pan-tumoral Small Molecule-Drug Conjugates targeting Fibroblast Activation Protein in solid lesions"

Dario Neri, co-founder, CEO and CSO, is giving a lecture entitled "Antibody-cytokine fusions directed against splice variants of fibronectin for the therapy of disseminated cancer: from discovery to Phase III clinical trials"

On November 5, 2021 AimedBio reported that its novel brain tumor therapeutics, AMB302, was selected as a government-initiated drug development program by the Korean Drug Development Fund (KDDF).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AMB302 is a first-in-class ADC therapeutics targeting a brain tumor specific fusion oncogene.

AimedBio has confirmed significant tumor killing effect of AMB302 candidate.

AimedBio utilizes patients’ genetic/clinical data and patient-derived samples in the antibody development process, resulting in higher probability of clinical success.

(Press release, AimedBio, NOV 5, 2021, View Source;s_keyword=&s_where=&start=20 [SID1234656924])

bluebird bio has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 5, 2021 Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported it will host a comprehensive Investor Update event on Thursday, December 2nd, from 10:00am ET – 1:00pm ET (Press release, Delcath Systems, NOV 5, 2021, View Source [SID1234595225]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature physicians discussing percutaneous hepatic perfusion, updated Focus trial data and the role of Hepzato Kit (melphalan hydrochloride for injection/Hepatic Delivery System) as a potential treatment for patients with hepatic-dominant metastatic ocular melanoma. Additionally, physicians will discuss the potential utility of Hepzato in treating colorectal cancer, intrahepatic cholangiocarcinoma, the unmet need in liver metastases and related clinical development strategies.

Event Details:

Event: Delcath Systems Virtual Investor Update Event
Date: Thursday, December 2, 2021
Time: 10:00am – 1:00 p.m. EST

To register for this event, please click here.

The live webcast of the event may be accessed through the Events and Presentation page of Delcath’s website, under the Investors section. The archived webcast and presentation will be available on the Company’s website after the event.

On November 5, 2021 Philogen reported that Stifel Conference provides an opportunity for investors to get a perspective of Philogen progresses and to meet CEO Dario Neri through a series of one-on-one meetings (Press release, Philogen, NOV 5, 2021, View Source [SID1234594677]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Co-founder, CEO and CSO, Prof. Dario Neri is giving a presentation on November 16, 2021.